Neural stem cells restore myelin in a demyelinating model of Pelizaeus-Merzbacher disease

2020 | journal article; research paper. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Neural stem cells restore myelin in a demyelinating model of Pelizaeus-Merzbacher disease​
Gruenenfelder, F. I; McLaughlin, M.; Griffiths, I. R; Garbern, J.; Thomson, G.; Kuzman, P. & Barrie, J. A. et al.​ (2020) 
Brain: A Journal of Neurology143(5) pp. 1383​-1399​.​ DOI: 

Documents & Media


GRO License GRO License


Gruenenfelder, Fredrik I; McLaughlin, Mark; Griffiths, Ian R; Garbern, James; Thomson, Gemma; Kuzman, Peter; Barrie, Jennifer A.; McCulloch, Maj-lis; Penderis, Jacques; Edgar, Julia M.
Abstract Pelizaeus-Merzbacher disease is a fatal X-linked leukodystrophy caused by mutations in the PLP1 gene, which is expressed in the CNS by oligodendrocytes. Disease onset, symptoms and mortality span a broad spectrum depending on the nature of the mutation and thus the degree of CNS hypomyelination. In the absence of an effective treatment, direct cell transplantation into the CNS to restore myelin has been tested in animal models of severe forms of the disease with failure of developmental myelination, and more recently, in severely affected patients with early disease onset due to point mutations in the PLP1 gene, and absence of myelin by MRI. In patients with a PLP1 duplication mutation, the most common cause of Pelizaeus-Merzbacher disease, the pathology is poorly defined because of a paucity of autopsy material. To address this, we examined two elderly patients with duplication of PLP1 in whom the overall syndrome, including end-stage pathology, indicated a complex disease involving dysmyelination, demyelination and axonal degeneration. Using the corresponding Plp1 transgenic mouse model, we then tested the capacity of transplanted neural stem cells to restore myelin in the context of PLP overexpression. Although developmental myelination and axonal coverage by endogenous oligodendrocytes was extensive, as assessed using electron microscopy (n = 3 at each of four end points) and immunostaining (n = 3 at each of four end points), wild-type neural precursors, transplanted into the brains of the newborn mutants, were able to effectively compete and replace the defective myelin (n = 2 at each of four end points). These data demonstrate the potential of neural stem cell therapies to restore normal myelination and protect axons in patients with PLP1 gene duplication mutation and further, provide proof of principle for the benefits of stem cell transplantation for other fatal leukodystrophies with ‘normal’ developmental myelination.
Issue Date
Brain: A Journal of Neurology 
TRR 274: Checkpoints of Central Nervous System Recovery 
TRR 274 | C01: Oligodendroglial NMDA receptors and NMDAR1 autoantibodies as determinants of axonal integrity in neuropsychiatric disease 
Working Group
RG Nave (Neurogenetics) 
External URL



Social Media